Antidepressant: Difference between revisions
imported>Robert Badgett (Started "Adverse effects") |
imported>Robert Badgett (→Classification: Started 'Heterocyclic antidepressants') |
||
| Line 3: | Line 3: | ||
==Classification== | ==Classification== | ||
===Tricyclic antidepressants=== | |||
{{main|Tricyclic antidepressant}} | |||
Tricyclic antidepressants are "substances that contain a fused three-ring moiety and are used in the treatment of [[depression]]. These drugs block the uptake of norepinephrine and serotonin into axon terminals and may block some subtypes of serotonin, adrenergic, and histamine receptors. However the mechanism of their antidepressant effects is not clear because the therapeutic effects usually take weeks to develop and may reflect compensatory changes in the central nervous system."<ref>{{MeSH|Tricyclic Antidepressive Agents}}</ref> | |||
===Heterocyclic antidepressants=== | |||
Heterocyclic antidepressants include trazadone and bupropion, and more recently, mirtazapine and nefazadone which are based on trazadone<ref name="isbn0-07-145153-6">{{cite book |author=Katzung, Bertram G. |authorlink= |editor= |others= |title=Basic and Clinical Pharmacology |edition=10th |chapter=Antidepressant Agents |chapterurl= |language= |publisher=McGraw-Hill Medical Publishing Division |location=New York |year=2006 |origyear= |pages= |quote= |isbn=0-07-145153-6 |oclc= |doi= |url=http://www.accessmedicine.com/resourceTOC.aspx?resourceID=16 |accessdate=}}</ref> | |||
===Second-generation antidepressants=== | ===Second-generation antidepressants=== | ||
{{main|Second-generation antidepressant}} | {{main|Second-generation antidepressant}} | ||
Second-generation antidepressants are a "structurally and mechanistically diverse group of drugs that are not [[tricyclic antidepressant|tricyclics]] or [[monoamine oxidase inhibitor]]s. The most clinically important appear to act selectively on serotonergic systems, especially by inhibiting serotonin reuptake."<ref>{{MeSH|Second-generation antidepressants}}</ref> | Second-generation antidepressants are a "structurally and mechanistically diverse group of drugs that are not [[tricyclic antidepressant|tricyclics]] or [[monoamine oxidase inhibitor]]s. The most clinically important appear to act selectively on serotonergic systems, especially by inhibiting serotonin reuptake."<ref>{{MeSH|Second-generation antidepressants}}</ref> | ||
===Monoamine oxidase inhibitors=== | ===Monoamine oxidase inhibitors=== | ||
Revision as of 08:43, 19 December 2008
Antidepressant medications are "mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several monoamine oxidase inhibitors are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (tricyclic antidepressant) also appear to act through brain catecholamine systems. A third group (second-generation antidepressant agents) is a diverse group of drugs including some that act specifically on serotonergic systems."[1]
Classification
Tricyclic antidepressants
Tricyclic antidepressants are "substances that contain a fused three-ring moiety and are used in the treatment of depression. These drugs block the uptake of norepinephrine and serotonin into axon terminals and may block some subtypes of serotonin, adrenergic, and histamine receptors. However the mechanism of their antidepressant effects is not clear because the therapeutic effects usually take weeks to develop and may reflect compensatory changes in the central nervous system."[2]
Heterocyclic antidepressants
Heterocyclic antidepressants include trazadone and bupropion, and more recently, mirtazapine and nefazadone which are based on trazadone[3]
Second-generation antidepressants
Second-generation antidepressants are a "structurally and mechanistically diverse group of drugs that are not tricyclics or monoamine oxidase inhibitors. The most clinically important appear to act selectively on serotonergic systems, especially by inhibiting serotonin reuptake."[4]
Monoamine oxidase inhibitors
Monoamine oxidase inhibitors are a "chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines".[5]
Adverse effects
Neuroleptic malignant syndrome
Serotonin syndrome
References
- ↑ Anonymous (2024), Antidepressant (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Anonymous (2024), Tricyclic Antidepressive Agents (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Katzung, Bertram G. (2006). “Antidepressant Agents”, Basic and Clinical Pharmacology, 10th. New York: McGraw-Hill Medical Publishing Division. ISBN 0-07-145153-6.
- ↑ Anonymous (2024), Second-generation antidepressants (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Anonymous (2024), Monoamine Oxidase Inhibitors (English). Medical Subject Headings. U.S. National Library of Medicine.